Washington D.C.: When it comes to depression, technology has a lot to answer for and now, a team of researchers has come up with a software that can help beat the blues.
A treatment for depression using Emotional Faces Memory Task (EFMT), a technology originally developed by two Mount Sinai researchers, resulted in a significantly greater reduction of major depressive disorder (MDD) symptoms compared to a control group, according to the initial clinical results.
EFMT is a cognitive-emotional treatment that is delivered via an app on the Click Neurobehavioral Intervention (CNI) platform, a clinically-validated patient engagement platform developed by Click Therapeutics.
This treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello and Dennis S. Charney.
The underlying mechanism for MDD that the intervention targets involves an imbalance in the activity of specific brain regions: individuals with MDD show hyperactivity of neural systems involved in emotion processing, such as the amygdala, coupled with decreased activity of systems involved in cognitive control and emotion regulation, such as the prefrontal cortex.
The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive centre of the brain, decides whether the incoming stimuli are noteworthy.
Patients using this therapeutic are asked to identify an emotion displayed in a series of faces, and for each face, they are asked to identify the number of faces earlier in the series in which they encountered the same emotion.
This aims to balance brain activity in these regions to work in concert with each other. In the trial, the therapeutic reduced MDD symptoms by 42 percent in the experimental group after six weeks compared to 15.7 percent in the control group, which was given a similar task using simple shapes instead of emotions.
“The aim is to target the thinking abnormality we see in patients with MDD – that of perseverating, ruminating, obsessing, dwelling on the negative – by activating these two nodes (emotion processing and cognitive control) simultaneously. Thus, higher cognitive control regions will stay active even while the brain is processing salient emotional stimuli, giving the individual the capacity to shift their mindfulness and attention so that they are not perseverating,” said Iacoviello.
The initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile. Iacoviello added, “We will be advancing these encouraging results to the next level, by incorporating this therapeutic into a highly engaging mobile platform and launching it through the CNI platform. It’s exciting to have the opportunity to test the program within a large health care system such as Mount Sinai.”
Charney said, “Mount Sinai embraces creativity, innovation, and entrepreneurship. This technology illustrates our strengths in translating health care discoveries from the academic setting into industry, and ultimately to the patients that will benefit from them.”
The study is presented at the Society of Biological Psychiatry Annual Scientific Convention.